Glafenine-associated hepatic injury. Analysis of 38 cases and review of the literature.
Glafenine was associated with hepatic injury in 38 cases. The causal relationship was assessed on the basis of the temporal relationship with drug use, course and exclusion of other causes. In 27 cases a causal relationship was considered likely, i.e. 'probable' (12 cases) or 'possible' (15 cases), whereas in 11 cases it was either unlikely or unclassifiable. In both the 'probable' and 'possible' groups 60-70% of individuals were women. Jaundice was present in three-quarters of cases in both groups. Eosinophilia was more frequent in the group of 'probable' cases, and this group had the highest case-fatality rate (42%). Onset varied from 2 days (after a rechallenge) to 8 months, but most cases appeared between 2 weeks and 4 months after starting therapy. Histology in 22 cases showed a predominantly hepatocellular pattern, varying from spotty panlobular necrosis, centrilobular and (sub)massive necrosis (acute pattern) to fibrosis and cirrhosis (chronic pattern). The chemical structure of glafenine and the clinicopathological pattern it induces resemble that of cinchophen. The incidence is unknown. Either metabolic idiosyncrasy or an immunoallergic mechanism seems to be responsible.
D000328:Adult; D000368:Aged; D056486:Chemical and Drug Induced Liver Injury; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced / Q000473:pathology; D005260:Female; D005897:Glafenine / Q000009:adverse effects*; D006801:Humans; D008103:Liver Cirrhosis / Q000139:chemically induced / Q000473:pathology; D008107:Liver Diseases / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009336:Necrosis / Q000139:chemically induced; D012737:Sex Factors; D062367:ortho-Aminobenzoates / Q000009:adverse effects*
D062367:ortho-Aminobenzoates; D005897:Glafenine